Jazz Pharmaceuticals (JAZZ) AI Stock Analysis

• Market Cap: $6.72B
• Dividend Yield: N/A
• Average Volume (3M): 725.45K
• Price to Earnings (P/E): 15.6
• Beta (1Y): 0.75
• Revenue Growth: 4.52%
• EPS Growth: -205.13%
• Country: US
• Employees: 2,800
• Sector: Healthcare
• Sector Strength: 40
• Industry: Biotechnology
• EPS (TTM): -8.25
• Shares Outstanding: 60,658,810
• 10 Day Avg. Volume: 943,630
• 30 Day Avg. Volume: 725,452
• PEG Ratio: 0.35
• Price to Book (P/B): 1.86
• Price to Sales (P/S): 1.87
• P/FCF Ratio: 5.65
• Enterprise Value/Market Cap: 1.53
• Enterprise Value/Revenue: 2.51
• Enterprise Value/Gross Profit: 3.80
• Enterprise Value/Ebitda: 44.41
• 1Y Price Target: $180.20
• Price Target Upside: 59.00% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 16

• Rating: 68 Neutral
• Price Target: $123.00 ▲(8.53% Upside)

Jazz Pharmaceuticals' overall stock score reflects a strong financial performance and positive corporate events, tempered by mixed technical indicators and valuation concerns. The company's strategic focus on neuroscience and oncology, along with upcoming regulatory milestones, supports a cautiously optimistic outlook.

Positive Factors

Clinical Trials

Zani GEA data remains the key catalyst for Jazz Pharmaceuticals, with a high probability of success based on the mechanism and prior data.

Product Launch

The better-than-expected launch of Ziihera in biliary tract cancer is a positive development for the oncology franchise.

Stock Valuation

The analyst reiterates a Buy rating on the stock due to its undemanding valuation and attractive risk/reward profile.

Negative Factors

Guidance

The company lowered its full-year sales guidance by approximately 1% at the midpoint.

Revenue Estimates

First quarter total revenues were a meaningful miss on Street estimates by 10%.

Sales Performance

Negative sales variances included Epidiolex sales of $252M vs an estimate of $267M, impacting stock performance.

Jazz Pharmaceuticals Business Overview & Revenue Model

Company Description

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older; Sunosi for the treatment of EDS in patients with narcolepsy and obstructive sleep apnea; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease; Vyxeos liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia; and Zepzelca for the treatment of adult patients with metastatic small cell lung cancer. The company also offers Xywav, an oxybate product candidate, to treat EDS and cataplexy with narcolepsy and idiopathic hypersomnia; JZP-324, a low sodium oxybate formulation with the potential to provide a clinically meaningful option for narcolepsy patients; JZP385, a T-type calcium channel modulator, for the treatment of essential tremor; JZP458, a recombinant Erwinia asparaginase, for use as a component of a multi-agent chemotherapeutic regimen in the treatment of pediatric and adult patients; and JZP150 for treatment of post-traumatic stress disorder. The company has licensing and collaboration agreements with ImmunoGen, Inc.; Codiak BioSciences, Inc.; Pfenex, Inc.; XL-protein GmbH; and Redx Pharma plc. Jazz Pharmaceuticals plc was incorporated in 2003 and is headquartered in Dublin, Ireland.

How the Company Makes Money

Jazz Pharmaceuticals generates revenue primarily through the sale of its pharmaceutical products. The company has a robust portfolio of approved therapies, which contribute to significant sales in both domestic and international markets. Key revenue streams include direct sales of its proprietary medications, royalties from licensing agreements, and collaborations with other pharmaceutical companies. The company also invests in research and development to create new products and expand its existing offerings, which can lead to additional revenue through market exclusivity and patent protection. Strategic partnerships and acquisitions further enhance its product pipeline and market reach, contributing to sustained financial growth.

Jazz Pharmaceuticals Financial Statement Overview

Summary

Jazz Pharmaceuticals maintains a healthy financial profile with strong profitability, efficient cash flow management, and moderate leverage. The company showcases consistent revenue growth and solid profit margins, although careful management of debt levels is essential to mitigate potential risks.

Income Statement

Jazz Pharmaceuticals shows a strong performance in profitability metrics, with a consistent gross profit margin of around 85%. The TTM net profit margin stands at approximately 11.86%, reflecting solid profitability, though slightly lower than the previous year due to a decrease in net income. Revenue growth has been positive, with a 5.55% increase from 2022 to 2023, although TTM figures show a slight decline compared to 2024. The EBIT and EBITDA margins have remained stable, highlighting efficient operational management.

Balance Sheet

The company's balance sheet reflects moderate leverage with a debt-to-equity ratio of approximately 1.3 TTM, which is manageable but indicates reliance on debt. Stockholders' equity has improved, showing a strong equity ratio of 36.2%. Return on Equity has improved significantly, marked at 11.55% TTM, reflecting effective use of equity despite a slight decline in net income. However, the significant debt levels pose a potential risk if not managed carefully.

Cash Flow

Jazz Pharmaceuticals demonstrates robust cash flow management with a strong operating cash flow to net income ratio of 3.23 TTM, indicating high cash generation efficiency. The free cash flow has been increasing, with a healthy growth rate of 10.4% from 2023 to 2024. The free cash flow to net income ratio is impressive at 3.09, reinforcing the company's ability to generate sufficient cash to support operations and growth.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	4.09B	4.07B	3.83B	3.66B	3.09B	2.36B
Gross Profit	2.70B	3.62B	3.40B	3.39B	2.65B	2.21B
EBITDA	230.96M	1.37B	1.23B	553.78M	718.41M	649.65M
Net Income	-404.84M	560.12M	414.83M	-224.06M	-328.95M	238.62M
Balance Sheet
Total Assets	10.94B	12.01B	11.39B	10.84B	12.30B	6.54B
Cash, Cash Equivalents and Short-Term Investments	1.19B	2.99B	1.63B	881.48M	591.45M	2.13B
Total Debt	1.08B	6.16B	5.79B	5.80B	6.14B	2.25B
Total Liabilities	7.24B	7.92B	7.66B	7.75B	8.33B	2.88B
Stockholders Equity	3.71B	4.09B	3.74B	3.09B	3.97B	3.66B
Cash Flow
Free Cash Flow	1.27B	1.35B	1.07B	773.78M	732.98M	520.39M
Operating Cash Flow	1.32B	1.40B	1.09B	1.27B	778.51M	899.65M
Investing Cash Flow	-789.15M	-508.19M	-163.06M	-446.23M	-5.21B	-1.01B
Financing Cash Flow	-699.84M	20.52M	-305.25M	-529.49M	3.97B	528.07M

Jazz Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 113.33
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JAZZ, the sentiment is Positive. The current price of 113.33 is below the 20-day moving average (MA) of 114.47, above the 50-day MA of 111.40, and below the 200-day MA of 118.61, indicating a neutral trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 51.01 is Neutral, neither overbought nor oversold. The STOCH value of 54.83 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JAZZ.

Jazz Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
HALO	79 Outperform	$7.36B	14.37	179.14%	―	34.97%	71.10%
JAZZ	68 Neutral	$6.72B	15.58	-10.84%	―	4.52%	-205.13%
MDGL	56 Neutral	$7.79B	―	-36.30%	―	3421.98%	49.62%
ROIV	56 Neutral	$7.59B	1.93	-15.84%	―	-85.32%	-111.82%
Sector *	54 Neutral	€4.18B	13.09	-41.26%	2.55%	14.43%	-26.74%
BBIO	53 Neutral	$9.38B	―	35.68%	―	7.62%	-55.29%
LEGN	48 Neutral	$6.81B	―	-29.70%	―	75.01%	-13.20%

Jazz Pharmaceuticals Corporate Events

Jazz Pharmaceuticals Shareholders Approve Key Proposals

On July 24, 2025, Jazz Pharmaceuticals held its annual general meeting of shareholders in Dublin, Ireland, where four key proposals were voted on. The shareholders elected four directors to serve until 2028, ratified KPMG as independent auditors, approved executive compensation, and granted the board authority to issue shares without pre-emption rights, indicating strong shareholder support for the company’s strategic decisions.

The most recent analyst rating on (JAZZ) stock is a Buy with a $183.00 price target. To see the full list of analyst forecasts on Jazz Pharmaceuticals stock, see the JAZZ Stock Forecast page.

Jazz Pharmaceuticals Appoints Renee Gala as New CEO

On July 8, 2025, Jazz Pharmaceuticals announced the appointment of Renee Gala as the new President and Chief Executive Officer, effective August 11, 2025. This leadership change follows a robust succession process and marks a significant milestone in the company’s long-term succession planning. Bruce Cozadd, the current CEO, will retire on September 12, 2025, but will continue as Chairperson of the Board. Gala, who has been with Jazz since 2020, has played a pivotal role in the company’s transformation and growth, and her appointment is expected to drive further value creation and sustainable growth for Jazz Pharmaceuticals.

The most recent analyst rating on (JAZZ) stock is a Buy with a $200.00 price target. To see the full list of analyst forecasts on Jazz Pharmaceuticals stock, see the JAZZ Stock Forecast page.